This article has been updated from a previous version, which incorrectly described the test as predictive instead of prognostic.
NEW YORK (GenomeWeb News) - Genomic Health said today it will work with Pfizer to develop a genomic test to estimate the risk of post-surgery recurrence of a carcinoma.